Glaxosmithkline plc, of London, said Incruse Ellipta (umeclidinium) received marketing authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow construction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The Canadian approval marks the first authorization granted for the product worldwide.